This is a news story, published by ScienceDaily, that relates primarily to Botensilimab news.
For more Botensilimab news, you can click here:
more Botensilimab newsFor more biology news, you can click here:
more biology newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
new colorectal cancer treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest colorectal cancer news, stable metastatic colorectal cancer news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
immunotherapyScienceDaily
•79% Informative
Study indicates that immunotherapy could tackle most common form of bowel tumour.
Consistent responses to immunotherapy have been reported in patients with the most common type of colorectal tumors, known as MSS mCRC.
61% of patients saw their tumor shrink or remain stable after receiving treatment.
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nature Medicine, 2024 ; DOI: 10.1038 /s41591-024-03083-7 Cite This Page:.
VR Score
85
Informative language
90
Neutral language
55
Article tone
formal
Language
English
Language complexity
80
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links